Updated labeling for IBAT inhibitors maralixibat and odevixibat related to hepatotoxicity and the fat-soluble vitamin deficiency sequela of bleeding

The U.S. Food and Drug Administration (FDA) is notifying health care professionals of safety-related changes to the prescribing information for the ileal bile acid transporter (IBAT) inhibitors, Livmarli (maralixibat) and Bylvay (odevixibat). These medications are indicated to treat cholestatic pruritus (persistent itching) in patients with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC).